ImmunityBio (IBRX) Change in Cash (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Change in Cash data on file, last reported at $117.0 million in Q1 2026.

• Change in Cash for Q1 2026 came in at $117.0 million, up 241.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $145.3 million (up 301.21% YoY), and the FY2025 annual result was -$54.5 million, up 55.3% from the prior year.
• Change in Cash improved to $117.0 million in Q1 2026 per IBRX's latest filing, from $28.1 million in the prior quarter.
• Over five years, Change in Cash peaked at $134.5 million in Q3 2023 and troughed at -$144.7 million in Q1 2022.
• A 5-year average of $1.5 million and a median of $480000.0 in 2022 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2023: Change in Cash tumbled 1582.14% in 2022, then soared 18127.08% in 2023.
• A 5-year view of Change in Cash shows it stood at $480000.0 in 2022, then soared by 18127.08% to $87.5 million in 2023, then sank by 63.87% to $31.6 million in 2024, then declined by 11.13% to $28.1 million in 2025, then surged by 316.6% to $117.0 million in 2026.
• Business Quant data shows IBRX's Change in Cash at $117.0 million in Q1 2026, $28.1 million in Q4 2025, and -$76.8 million in Q3 2025.